Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.32 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.32 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.32 |
| ▸ | PRKAG3 | Q9UGI9 | 1/20 | 0.32 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.32 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4020234 | 0.91 | ABL1 (0.36) | — | |
| SCHEMBL4013900 | 0.90 | ALDH1A1 (0.33) | XDHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL13494177 | 0.83 | XDH (0.34) | XDHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL13650031 | 0.81 | — | — | |
| SCHEMBL16496977 | 0.81 | RET (0.36) | — | |
| SCHEMBL13650035 | 0.80 | — | — | |
| SCHEMBL19025097 | 0.79 | XDH (0.35) | XDHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL1738426 | 0.79 | XDH (0.35) | XDHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL13494110 | 0.77 | ADK (0.38) | XDHPRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL13494103 | 0.77 | ADK (0.34) | XDHPRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-10-08 | — | — | US | disclosed |
| US-7524825-B2 | Tricyclic-nucleoside compounds for treating viral infections | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-28 | — | — | US | disclosed |
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. | 2009-02-19 | — | — | US | disclosed |
| US-20060252715-A1 | Tricyclic-nucleoside compounds for treating viral infections | GENELABS TECHNOLOGIES, INC. | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048189-A1 | TRICYCLIC-NUCLEOSIDE COMPOUNDS FOR TREATING VIRAL INFECTIONS | TYMP, PNP, NSUN2 | XDH 162/4885PRKAB2 4557/4885PRKAG1 4505/4885 |
| US-20060252715-A1 | Tricyclic-nucleoside compounds for treating viral infections | PNP, TYMP, NSUN2 | XDH 205/4885PRKAB2 4439/4885PRKAG1 4401/4885 |
| US-20090253648-A1 | Tricyclic-Nucleoside Compounds for Treating Viral Infections | PNP, TYMP, NSUN2 | XDH 205/4885PRKAB2 4439/4885PRKAG1 4401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.